

# miR-138-5p-mediated HOXD11 promotes cell invasion and metastasis by activating the FN1/MMP2/MMP9 pathway and predicts poor prognosis in penile squamous cell carcinoma

**Xingliang Tan**

Sun Yat-sen University Cancer Center <https://orcid.org/0000-0002-4015-4982>

**Yanjun Wang**

Sun Yat-sen University Cancer Center

**Zhingming Wu**

Cancer Center, Sun Yat-sen University

**Yuantao Zou**

Sun Yat-sen University Cancer Center

**Sihao Luo**

Sun Yat-sen University Cancer Center

**Yi Tang**

Sun Yat-sen University Cancer Center

**Dong Chen**

Sun Yat-sen University Cancer Center

**Gangjun Yuan**

Chongqing University Cancer Hospital

**Kai Yao** (✉ [yaokai@sysucc.org.cn](mailto:yaokai@sysucc.org.cn))

Sun Yat-sen University Cancer Center

---

## Article

**Keywords:** penile squamous cell carcinoma, HOXD11, miR-138-5p, FN1, MMPs, tumor metastasis

**Posted Date:** July 26th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1824198/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published at Cell Death & Disease on September 23rd, 2022. See the published version at <https://doi.org/10.1038/s41419-022-05261-2>.

# Abstract

## Background

Regional lymph node and distant metastasis are the most radical causes of high mortality in penile squamous cell carcinoma (PSCC) patients. However, the available biomarkers and detailed mechanisms underlying the metastasis of PSCC remain elusive. Here, we detected that HOXD11 was upregulated in tumors, especially in metastatic lymph nodes, highlighting its role in the progression of PSCC. We aimed to further explore the clinical significance, biofunctions and specific mechanisms of HOXD11.

## Methods

Twelve PSCC tumors, metastatic lymph nodes and corresponding normal tissue pairs were examined by an RNA-seq panel of HOX genes to explore progressive biomarkers. The expression of HOXD11 was detected by qPCR and western blotting in our newly established PSCC cell lines. The clinical relevance and outcomes of HOXD11 were further validated in a large cohort of 267 PSCC patients by immunohistochemistry. Functional experiments *in vitro* and subcutaneous xenograft and footpad metastatic models were conducted to investigate the of HOXD11. The targeting relationship and mechanisms between HOXD11, miR-138-5p and FN1 were demonstrated by dual luciferase reporter assays and chromatin immunoprecipitation.

## Results

HOXD11 expression was upregulated in PSCC tissues, especially in metastatic lymph nodes. High HOXD11 expression was associated with aggressive features, such as advanced pN stages, extranodal extension, pelvic lymph node and distant metastasis, and predicted poor survival. Furthermore, knockdown of HOXD11 not only inhibited cell proliferation, invasion and tumor growth but also reduced the burden of metastatic lymph nodes. Besides, miR-138-5p and FN1 reversed HOXD11-mediated oncogenic capacity. Mechanistic studies indicated that HOXD11 was post-transcriptionally regulated by miR-138-5p, bound to the promoter regions of FN1 activating the FN1/MMP2/MMP9 pathway to decompose the extracellular matrix and promoted epithelial mesenchymal transition-like phenotype metastasis.

## Conclusions

HOXD11 promotes PSCC progression, predicting advanced disease with poor outcomes. HOXD11 could be a promising prognostic biomarker and potential therapeutic target for PSCC.

## 1. Background

Penile squamous cell carcinoma (PSCC), which accounts for the vast majority of ( $\geq 95\%$ ) penile cancers, is a devastating malignancy in males both physically and psychologically[1–3]. The presence and extent of lymph node metastasis, with a dramatic decline in 5-year overall survival rates from 90% to 29–59%, are the most fatal prognostic factors in PSCC[4–6]. Despite the rapid development of comprehensive therapies[7, 8], the existing treatments are still unsatisfactory and lack available targeted therapies[9]. The detailed mechanisms behind tumor progression remain elusive. Although a recent genetic understanding of PSCC has shown that HRAS mutations, EGFR amplifications, and dysregulation of CAV1 and IDO1 are associated with advanced disease[10–12], most studies lack specific mechanisms owing to the lack of appropriate PSCC cell lines, convincing metastatic experiments *in vivo* and large-scale clinical validations. Our previous studies have established a molecular stratification to predict high-risk PSCC patients with lymph node metastasis[13, 14], but the mechanism needs to be further explored in depth. Therefore, exploring effective biomarkers in PSCC and clarifying the underlying mechanisms in tumor metastasis to improve outcome are imminent and difficult issues.

Homeobox (HOX) gene clusters encode a series of highly conserved transcription factors that are essential for tumorigenesis by regulating cell differentiation, angiogenesis and metastasis[15, 16]. The dysregulation of HOX genes was associated with numerous solid malignancies and leukemia, suggesting its prominent roles in tumor progression[15–20]. However, the expression pattern of HOX clusters and their oncogenic roles remain unknown in PSCC.

In the present study, we explored the expression landscape of HOX genes in PSCC and highlighted that homeobox D11 (HOXD11) was indispensable in the progression of PSCC. HOXD11, located at chromosome 2q31.1, is involved in neoplastic transformation, especially the processes of tumor invasion and metastasis, in previous studies[16]. Kristina *et al.* reported that knockdown of the expression of HOXD11 repressed tumor growth and lung metastasis in Ewing's sarcoma[19]. In addition, the overexpression of HOXD11 was a poor prognostic biomarker in head and neck squamous cell carcinoma and gliomas by promoting tumor proliferation and invasion[17, 20]. Our results first revealed a significant association between HOXD11 expression and clinicopathological features as well as poor outcomes in a large PSCC cohort. We aimed to investigate the biological functions of HOXD11 in PSCC and subsequently explored the potential mechanisms in metastasis.

Herein, we demonstrated that HOXD11 was post-transcriptionally regulated by miR-138-5p at 3' untranslated region (UTR) and degraded its expression. Meanwhile, HOXD11 bound to the promoter regions of fibronectin 1 (FN1), activating the expression of MMP2 and MMP9 to decompose the extracellular matrix (ECM) and promoting cell invasion and metastasis through the epithelial mesenchymal transition (EMT) phenotype *in vitro* and *in vivo*. These findings provide new insight into HOXD11-mediated PSCC progression and present a potential therapeutic target for tumor metastasis.

## 2. Methods

### 2.1. Patients, tissue specimens and research ethics

This study was conducted on a total of 267 PSCC patients with well-preserved paraffin-embedded tumor specimens that had been pathologically confirmed according to the TNM Staging System for Penile Cancer (8th ed., 2017) at the Sun Yat-sen University Cancer Center (SYSUCC) from 2003 to 2021. Among them, 12 pairs of matched tissues from pN + PSCC patients were retrieved for HOX gene expression pattern screening. Then, 93 fresh frozen tumor samples and 21 normal tissues were retrieved for mRNA and protein extraction. The study was approved by the SYSUCC Ethics Committee (GZR2019-167), and informed consent was acquired.

## **2.2. RealTime quantitative polymerase chain reaction (qPCR)**

The progression target gene screening was based on the mRNA expression panel of the HOX gene cluster. Total RNA extraction, reverse transcription and cDNA amplification were performed according to the standard protocol as described previously. Relative target gene expression was quantified by the  $2^{(-\Delta\Delta Ct)}$  method and normalized against GAPDH. Detailed information on primer sequencing is listed in **Table S1**.

## **2.3 Western blot (WB)**

Tissues and cells were lysed in RIPA buffer (Beyotime) containing 1% protease inhibitors at 4°C for 30 min, and the concentration of proteins was detected by Coomassie Brilliant Blue G250 (Beyotime) according to the manufacturer's protocol. Equal amounts of protein (30 µg) were separated by 10–15% SDS–PAGE and transferred to PVDF membranes (Pierce Biotechnology). The membranes were blocked with 5% nonfat milk and incubated according to the recommended conditions for the primary and secondary antibodies. The bands were visualized by ECL reagents (EpiZyme). Antibodies and dilutions are listed in **Table S2**.

## **2.4 Cell lines and cell culture**

The PSCC cell lines Pen11, Pen12, 149rca, 149rm and 156lm were established in our laboratory as previously reported. The human epidermis keratinocyte cell line (HaCaT) was purchased from the Chinese Academy of Sciences (Shanghai, China). Cell lines were maintained in 10% fetal bovine serum DMEM with 1% penicillin and 1% streptomycin (Gibco), and cells were cultured at 37°C in a 5% CO<sub>2</sub> incubator.

## **2.5 Plasmids, transfection and lentiviral infection**

Short hairpin RNA (shRNA) and negative control (NC) sequences were cloned into the lentiviral vector GV248 (hU6-MCS-Ubiquitin-IRES-puromycin) to silence HOX genes (Shanghai Genechem Co., Ltd.). The full-length human HOXD11 gene was amplified and cloned into a vector (pcDNA3.1) to generate HOXD11 overexpression plasmids. Lentiviral packaging and infection were performed using 293T cells as previously described. To silence FN1, small interfering RNAs (siRNAs) were designed and synthesized by GenePharma (Shanghai, China) and transfected with Lipo8000™ Transfection Reagent (Beyotime). The effective sequences were as follows: shHOXB2, TTAAGTGAATTAGCGTTTAATC; shHOXD10,

TCGTAATGCAGGGTAACTATT; HOXD11-sh1, GGTTTAATGACGTCTCTTCTC; HOXD11-sh2, CGCGAACTGGAACGCGAGTTT; siFN1-F: GCAGCACAACUUCGAAUUATT.

## 2.6 Cell Proliferation and Invasion Assays

Clone formation assays and Cell Counting Kit-8 (CCK-8) assays were conducted to detect the proliferation potential of PSCC cells *in vitro*. In brief, 2000 cells were seeded in 6-well plates, and the number of cell colonies was counted after 14 days. Similarly, 1500 cells were cultured with 100  $\mu$ l medium in 96-well plates and incubated with 10  $\mu$ l CCK-8 solution (Dojindo, Japan) for 2 hours. The absorbance was read on a spectrophotometer at 450 nm for 7 consecutive days. In addition, wound healing assays and Matrigel Transwell invasion assays were used to evaluate the progressive capability of cells as described in our previous study[21].

## 2.7 Tumor xenograft assays

For the subcutaneous xenograft tumor model, 5–7-week-old BALB/c nude mice (Jiangsu GemPharmatech Co., Ltd.) were randomly divided into two groups (n = 6) and were injected subcutaneously with  $5 \times 10^5$  Penl2-shNC or Penl2-shHOXD11 cells. Tumors were harvested after 3 weeks and subjected to IHC assays. Furthermore, we established a lymph node metastasis xenograft model to explore the spontaneous metastatic capability of PSCC cells. A total of  $1.2 \times 10^5$  Penl2-shNC or Penl2-shHOXD11 cells (5 mice per group) in 100  $\mu$ l PBS were injected into the right footpad in nude mice, and popliteal lymph nodes were exposed and harvested after 6 weeks. Tumor volume was calculated as follows: Volume ( $\text{mm}^3$ ) =  $0.5 \times \text{length} \times \text{width}^2$ . In addition, mice were euthanized when the volume of the tumor exceeded 1500  $\text{mm}^3$  or weight loss exceeded 15%. The Experimental Animal Ethics Committee of SYSUCC (L102012019002 V) approved the animal experiments.

## 2.8 Immunofluorescence (IF)

A total of 1000 cells were cultured in 35-mm confocal dishes. After incubation for 24 hours, the cells were fixed in 4% paraformaldehyde for 15 minutes, permeabilized with Triton X-100 (Beyotime) for 10 minutes and blocked with QuickBlock™ Blocking Buffer (Beyotime) for another 10 minutes. The cells were then incubated with corresponding primary and secondary antibodies (**Table S2**) along with DAPI (Sigma, F6057) for visualization using confocal microscopy.

## 2.9 Immunohistochemistry (IHC) and immunocytochemistry (ICC)

For IHC staining, 4- $\mu$ m paraffin-embedded tissue sections were processed according to standard pathologic procedures as previously described[21]. For ICC, cells were seeded on glass slides in 12-well plates and fixed in 4% paraformaldehyde for 15 minutes. The following steps were similar to the IHC procedures. Pathological diagnosis and IHC staining scores were determined by two independent pathologists (LLL and CKM). If the scores were different, the results were redetermined after discussion. HOXD11 staining scores were multiplied by the staining intensity (0 for faint, 1 for weak staining and 2

for strong staining) and staining area (positive staining proportion of nuclei: 1 for 1–10%, 2 for 11–50%, and 3 for 50% above). The cutoff value was calculated by X-Tile software (version 3.6.1) as previously described[22]. In our cohorts, HOXD11 staining scores of 0–2 points were regarded as low expression, and 3–6 points were regarded as high expression.

## 2.10 miRNA prediction and validation

Two bioinformatics tools, TargetScan [23] and starBase [24] were used to predict the MicroRNAs (miRNAs) for HOXD11. The expression level of target miRNA in tumor and corresponding normal tissues and prognostic outcomes were detected by OncoMiR [25] and KM Plotter [26] websites in Pan-cancers. MiPure Cell/Tissue miRNA Kit (Vazyme), miRNA 1st Strand cDNA Synthesis Kit (Vazyme) and miRNA Universal SYBR qPCR Master Mix (Vazyme) were used for miRNA extraction, cDNA reverse transcription (primer: 5' GTCGTATCCAGTGCAGGGTCCGAGGTATTTCGCACTGGATACGACCGGCCT 3') and amplification (forward primer: 5' GCGAGCTGGTGGTGTGAATC 3') according to the manuscript respectively. The mimics and inhibitors of miR-138-5p were synthesized by GenePharma Co., Ltd. (Shanghai, China). We also constructed the wild-type and mutant 3'UTR dual luciferase reporter vectors of HOXD11 by RiboBio Co., Ltd. (Guangzhou, China), and the detailed procedures were similarly described in the section of Methods "2.11 Dual Luciferase reporter assay".

### 2.11 Dual Luciferase reporter assay

To generate luciferase reporter plasmids, the human FN1 promoter sequences (nucleotide from + 1397 to -244) and the human THBS1 promoter sequences (nucleotide from - 1040 to + 204) were cloned into the pGL3-basic plasmid (Promega). A total of  $5 \times 10^4$  HOXD11-overexpressing or shHOXD11 cells and corresponding control cells were cultured in 24-well plates in triplicate for 24 h and then cotransfected with pGL3-FN1 or pGL3-THBS1, *Renilla*, and pGL3-basic control plasmids. After transcription for 48 h, luciferase and *Renilla* signals were detected by a Dual Luciferase Reporter Assay Kit (Promega, E1980), and the ratio was calculated and normalized to *Renilla* luciferase activity.

### 2.12 Chromatin immunoprecipitation-qPCR (ChIP–qPCR)

The JASPAR database was used to predict the binding sites of HOXD11 and the FN1 promoter regions. The UCSC Genome Browser was used to detect the chromatin states of the promoter regions (H3K27Ac, H3KMe1 and H3KMe3). The ChIP assays were performed using the SimpleChIP® Enzymatic Chromatin IP Kit (CST, #9003) according to the manufacturer's instructions. In brief, HOXD11-Flag overexpression and vector PSCC cells were cross-linked using 1% formaldehyde for 10 minutes and were lysed and sonicated to fragments of DNA. Samples were purified through immunoprecipitation with Flag antibody (CST, #14793), conjugated with protein A/G beads, and reversal of cross-linking. Eluted DNA fragments were purified and analyzed by qPCR. The primers are listed in **Table S3**.

### 2.13 Bioinformatics analysis

RNA sequencing (RNA-seq) was performed to compare the different expression patterns between Pen12 shNC and HOXD11-sh1 cells. R software was used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses using the clusterProfiler package. Gene-set enrichment analysis (GSEA) was conducted by GSEA tools version 4.1 (<http://www.broadinstitute.org/gsea>) as previously described [21].

## 2.14 Statistical analysis

Statistical analysis was performed using SPSS software (Version 25.0). Statistics are presented as the means  $\pm$  SDs. The differences between two groups were analyzed by Student's t test or one-way ANOVA. The composition ratios were determined by the chi-square test. Survival analysis was performed with Kaplan–Meier survival curves and a multivariate Cox proportional hazards regression model by the forward method. The correlations between genes were analyzed by Pearson correlation analysis. A p value  $< 0.05$  was considered significant.

## 3. Results

### 3.1 HOXD11 is a potential oncogene promoting tumor progression in PSCC.

To investigate the oncogenic roles of HOX clusters in PSCC, qPCR was performed to detect the mRNA expression of 34 HOX genes in 12 paired PSCC tissues, including normal squamous epithelium (N), primary penile carcinoma (PCA) and metastatic lymph node tissues (LM). The expression profiles are shown in Fig. 1A. We found a striking increase in the expression of HOXB2, HOXD10 and HOXD11 in tumors, especially with the highest expression in LM tissues, compared with N tissues (Fig. 1B). For each patient, HOXD10 and HOXD11 but not HOXB2 mRNA expression was gradually elevated in LM, PCA and N tissues, indicating the oncogenic potential of tumor aggressiveness in PSCC (Fig. 1C and Fig. S1). Subsequently, we inhibited the expression of three target genes in Pen11 PSCC cells and performed Transwell invasion assays (Fig. S2). We observed a reduction in invasive cells in the HOXD11-silenced group but without significance in the shHOXD10 or shHOXB2 group. These data indicated that HOXD11 might serve as a novel oncogene promoting the progression of PSCC.

### 3.2 HOXD11 is overexpressed in PSCC tissues and cell lines.

To further validate the protein expression of HOXD11 in PSCC, WB assays were performed with tissue samples in pairs from 10 PSCC patients (including 4 pN+ patients) and cell lines. Consistent with the qPCR results, HOXD11 proteins were highly expressed in PSCC cell lines as well as tumors, especially in lymph node metastatic tissues, compared with normal controls (Fig. 1D). In addition, IHC was performed with an mPSCC patient with retroperitoneal lymph node metastases, and we found that HOXD11 was strongly expressed in tumors, especially in metastatic lesions (Fig. 1E). Subsequently, qPCR assays were

conducted in a larger cohort of 93 PSCC tumor and 21 normal tissues. The results showed that HOXD11 mRNA levels were overexpressed in tumors ( $t = 3.312$ ,  $p = 0.001$ ) (Fig. 1F). More importantly, overexpression of HOXD11 was associated with advanced disease, such as T grade, lymph node metastasis and extranodal extension (ENE), indicating the clinical significance of poor outcomes (Fig. 1F).

### **3.3 Elevated expression of HOXD11 is associated with poor clinical features and survival in PSCC.**

To further determine the association between HOXD11 expression and the clinicopathological features of PSCC, 267 PSCC tumor sections were subjected to IHC staining. The IHC scoring criteria are described in detail in the Methods. HOXD11 was subjected to nuclear staining, and the staining patterns and distribution are shown in **Fig. S3**. In our cohort, 89/267 (33.3%) patients died of PSCC, with a median follow-up time of 59.1 months. The IHC results indicated that 182 (68.2%) patients had low HOXD11 expression (IHC score 0–2), while 85 (31.8%) patients overexpressed HOXD11 (IHC score 3–6) (**Table. 1**). Chi-square tests demonstrated that high expression of HOXD11 was correlated with poor clinical features, including pT ( $p = 0.003$ ), pN ( $p < 0.001$ ), M status ( $p < 0.001$ ), clinical stage ( $p < 0.001$ ), pathological grade ( $p = 0.011$ ), ENE ( $p < 0.001$ ) and pelvic lymph node metastasis ( $p = 0.038$ ) (**Table. 1**).

Then, Kaplan–Meier survival analysis revealed that HOXD11 overexpression led to a poor 5-year cancer-specific survival (CSS) rate ( $p < 0.001$ ). Other clinical features, such as pathological grade and pT2–pT4, pN+, M and ENE subgroups, were also associated with a shorter 5-year CSS rate (all  $p < 0.05$ ) (Fig. 2B–F). Moreover, multivariate analysis revealed that HOXD11 expression ( $p = 0.016$ , HR = 1.759; 95% CI: 1.112–2.782) and pN status were both independent prognostic indicators of PSCC (**Table. 2**). Taken together, these data suggested that the overexpression of HOXD11 was a novel biomarker contributing to poor clinical prognosis in PSCC.

### ***3.4. HOXD11 regulates PSCC cell proliferation, migration and invasion in vitro.***

To explore the oncogenic functions of HOXD11 in PSCC, we first established HOXD11-silenced (Pen1 and Pen2) and HOXD11-overexpressing (149rm) cell lines and validated the protein expression by WB (Fig. 3A). We found that knockdown of HOXD11 in Pen1 and Pen2 cells significantly impaired the proliferation ability (Fig. 3B), reduced the clone and Transwell invaded cell numbers (Fig. 3D, E) and retarded healing of scratch wounds (Fig. 3F) compared with the negative control (NC). Conversely, when we overexpressed HOXD11 in 149rm cells, cell proliferation, migration and invasion were consistently improved (Fig. 3B–F). Moreover, to further validate HOXD11-mediated tumorigenesis in PSCC, we rescued and reupregulated the expression of HOXD11 in Pen1/Pen2-sh1 cells (Fig. 3C). The results indicated that rescuing HOXD11 expression reactivated cell vitality, promoting cell proliferation (Fig. 3B), increasing the number of clones and invaded cells (Fig. 3D, G) and accelerating wound healing (Fig. 3H). These observations revealed that HOXD11 participated in the tumor progression of PSCC.

### ***3.5 Knockdown of HOXD11 inhibits tumor growth and lymph node metastasis in vivo.***

To further detect the tumorigenicity ability *in vivo*, a subcutaneous xenograft tumor model was established in nude mice. After 3 weeks of incubation, the tumors formed by Pen12 HOXD11-silenced cells were significantly smaller than those formed by Pen12-NC cells (Fig. 4A). IHC was performed with subcutaneous tumors to identify the knockdown efficiency of HOXD11 (Fig. 4A). Then, to better mimic the *in vivo* metastatic process of PSCC, we established lymph node metastasis models by inoculating shHOXD11 or NC cells into mouse foot pads. We found that the size of popliteal lymph nodes shrank dramatically when HOXD11 expression was knocked down (Fig. 4B). HE staining also confirmed the reduction of lymph nodes with metastases (Fig. 4B). Therefore, our results demonstrated that knockdown of HOXD11 impaired tumor growth and lymph node metastasis *in vivo*.

### **3.6 Extracellular matrix regulation contributes to HOXD11-mediated tumor metastasis in PSCC.**

To further explore the molecular mechanism by which HOXD11 promotes the progression of PSCC, transcriptome sequencing was performed in shHOXD11-transfected Pen12 and control cells. The GO enrichment and KEGG pathway analyses showed that the biological function of tumor metastasis via epithelial mesenchymal transition (EMT) was significantly enriched when HOXD11 was inhibited in PSCC (Fig. 5A and Fig. S4). The differentially expressed genes involved in EMT are shown in the heatmap (Fig. 5B). Furthermore, GSEA showed that knockdown of HOXD11 induced the process of EMT through the degradation of extracellular matrix (ECM), which was reported to be a major driver of the loss of adherens junctions in epithelial cells promoting metastasis (Fig. 5C).

To clarify how the transcription factor HOXD11 promoted ECM-mediated tumor progression, qPCR was performed to detect the mRNA expression of downstream ECM-associated targets. The results indicated that overexpression of HOXD11 in Pen11 and Pen12 cells dramatically increased FN1 and THBS1 expression, while FN1 and THBS1 were inhibited correspondingly in HOXD11-silenced cells (Fig. 5D). Dual luciferase reporter assays further demonstrated that HOXD11 overexpression increased whereas HOXD11 knockdown attenuated the transcriptional activation of FN1 in the Pen11 and Pen12 cells (Fig. 5E). However, when the THBS1 promoter plasmid was transfected into HOXD11 overexpression or knockdown cells, the luciferase activity of THBS1 did not change significantly, indicating that HOXD11 did not bind to the THBS1 promoter to regulate its transcription (Fig. 5E). Collectively, these data suggested that HOXD11 might induce FN1 transcription by participating in ECM-mediated EMT and promoting tumor metastasis in PSCC.

### **3.7 HOXD11 directly binds with the promoter regions of FN1 and upregulates its expression.**

To further clarify the mechanism underlying the regulation of FN1 expression by HOXD11, we used the JASPAR database to analyze and predict 6 regions (P1-P6) of the FN1 promoter containing HOXD11 binding sites (Fig. 5F). The UCSC Genome Browser showed a visible increase in H3K27 acetylation and H3K4 methylation, indicating open and active chromatin in these regions[27], which might include transcription factor-binding sites (Fig. 5F). ChIP–qPCR assays indicated that HOXD11 can directly bind to the promoter of FN1 at P2 sites (Fig. 5F). Then, we reconstituted and cotransfected the FN1 promoter plasmids with mutant P2 binding sites. The results demonstrated that the luciferase activity of the Mut-P2 reporter gene significantly decreased compared with that of the wild-type group (Fig. 5H). Moreover, ChIP–qPCR assays confirmed that HOXD11 did not bind to the mutant P2 regions of the FN1 promoter (Fig. 5I). Taken together, these findings clarified that the HOXD11 transcription factor can specifically bind to FN1 promoter regions at P2 sites and promote its transcription.

### **3.8 HOXD11 degrade extracellular matrix to promote metastasis via FN1/MMP2/MMP9 axis in PSCC.**

Recent studies have demonstrated that FN1 activates matrix metalloproteinase 2 (MMP2) and MMP9 expression to hydrolyze components of the basement membrane and thus can promote tumor invasion and metastasis in various cancers[28–31]. To explore the expression of FN1 in PSCC and the relationship between HOXD11 and MMPs, qPCR was performed in 24 PSCC patients. We detected that FN1 was upregulated in PSCC tumor tissues (Fig. 6A). Pearson correlation analysis showed that HOXD11 and FN1 ( $p = 0.020$ ;  $R^2 = 0.222$ ) as well as FN1 and MMP2 or MMP9 ( $p = 0.045, 0.000$ ;  $R^2 = 0.170, 0.575$ ) were positively correlated, indicating linear regulation in PSCC (Fig. 6B). Subsequently, the WB results clarified that knockdown of HOXD11 in Pen1 and Pen2 cells decreased FN1 as well as MMP2 and MMP9 expression (Fig. 6C). Consistent with the WB results, ICC assays also indicated the downregulation of FN1, MMP2 and MMP9 in HOXD11-silenced Pen1 cells (Fig. 6D). In addition, IF assays showed that FN1, MMP2 and MMP9 were increased by overexpression of HOXD11 in 149 BCa cells but were rescued when the expression of FN1 was subsequently suppressed by transfection with si-FN1 (Fig. 6E). These data suggested that HOXD11 promoted FN1 transcription and activated the downstream MMP2 and MMP9 proteins in PSCC.

Next, we investigated whether FN1 activation was required for the ability of HOXD11 to promote cell invasion in PSCC. Silencing FN1 not only reduced the number of invasive cells through the Matrigel-coated Transwell chambers in Pen1 and Pen2 cells but also in corresponding HOXD11-overexpressing cells. Moreover, the expression of MMP2 and MMP9 was reversed when FN1 expression was knocked down in HOXD11-overexpressing cells, which suggested the indispensable role of FN1 in HOXD11-mediated tumor progression (Fig. 6F-G). Taken together, we demonstrated that the HOXD11/FN1/MMP2/MMP9 axis was an underlying molecular mechanism promoting tumor invasion and metastasis via an EMT-like phenotype in PSCC.

### **3.9 miR-138-5p inhibited cell progression by targeting and repressing HOXD11 expression**

The role of miRNA via targeting the mRNA region of 3'-UTR is involved in the degradation of target genes[32]. To further investigate the upstream regulator of HOXD11 in PSCC, the miRNAs targeting HOXD11 were predicted by bioinformatics tools and revealed that HOXD11 3'-UTR contains a potential miR-138-5p-binding site. MiR-138-5p serves as tumor suppressor gene which was down-regulated and predicted better prognosis in several squamous cell carcinoma but was uncertain in PSCC (**Fig. S5 and Table. S4**). Hence, qPCR was performed in 24 patients and the results indicated that miR-138-5p was low expressed in PSCC tumors with negative correlation between HOXD11 expression (Fig. 7A-B). Transfecting with miR-138-5p mimics in Pen12 cells significantly decreased luciferase activity of reporter gene with wild-type HOXD11 3'UTR, while increased with the transfection of miR-138-5p inhibitors in comparison with miR-control (Fig. 7C-D). However, this regulatory effect of miR-138-5p was suppressed when the binding site of HOXD11 3'UTR was mutated (Fig. 7C-D), suggesting an exact regulatory relationship between miR-138-5p and HOXD11. WB verified that miR-138-5p mimics inhibited the expression of HOXD11 while by miR-138-5p inhibitors promoted its expression (Fig. 7E). Matrigel-coated Transwell assays showed that miR-138-5p was tumor suppressor inhibiting cell invasion in PSCC cell lines (Fig. 7F). More importantly, the recovery experiments demonstrated that the invasive cells were reversed when transfecting with miR-138-5p mimics in HOXD11 overexpression 149rca cells by suppressing the FN1/MMP2/MMP9 axis in PSCC (Fig. 7G-H).

## Discussion

Regional lymph node metastasis, accounting for 20–50% of newly diagnosed patients, is a common and crucial unfavorable prognostic factor in PSCC[1–3]. Even if patients receive contemporaneous radical inguinal lymph node dissection, the 5-year CSS rates (pN1: 74.1%, pN2: 44.7%, pN3: 9.5%) are poor[1, 13]. Moreover, PSCC patients with distant metastasis have ominous findings owing to the low chance of surviving over 5 years[1]. Currently, chemotherapy options and efficacy are limited in PSCC, and there is still a lack of available targeted therapies in clinical practice and relevant basic research[3, 8]. Several studies have reported that RAB20 and IDO1 overexpression promote cell proliferation and induce immunosuppression in PSCC[12, 21]. Other serum biomarkers, such as CXCL5, CXCL13 and CCL20, are associated with nodal metastasis in small cohorts[33–35]. The mechanisms underlying tumor metastasis are uncertain and have become an imminent issue.

To overcome the above difficulties and explore available biomarkers in the progression of PSCC, we performed an RNA-seq panel in 12 paired PSCC patients, including normal, primary tumor and metastatic lymph node tissues, and determined that HOXD11 was upregulated and involved in tumor metastasis. Further qPCR, WB and IHC assays confirmed that HOXD11 was overexpressed in PSCC cell lines and tumor samples, especially with the highest expression in corresponding metastatic lymph node tissues. Our results first suggested that the HOXD11 transcription factor, as a potential oncogene, was upregulated in PSCC, especially in metastatic lymph nodes, suggesting a dominant role in the process of PSCC metastasis.

As previously described, HOXD11 is involved in tumorigenesis and tumor progression in several cancers. Harada and Xu et al. found that hypermethylation of HOXD11 in the oral epithelium was an early

dangerous event in lung cancer[36, 37]. Similarly, high methylation levels of HOXD11 are also regarded as poor indicators in breast cancer and ovarian cancer[38, 39]. In the regulation of transcription, HOXD11 overexpression participated in head and neck squamous cell carcinoma, laryngeal squamous cell carcinoma, glioma and hemangioblastoma by promoting cell proliferation, cell migration and angiogenesis[15, 17, 20, 40]. In addition, Heyking et al. demonstrated that HOXD11 promoted lung metastasis in Ewing sarcoma[19]. However, the clinical significance and biological functions of HOXD11 in PSCC have not been elucidated.

To this aim, we performed IHC to detect HOXD11 expression in a large PSCC cohort. We detected that HOXD11 overexpression served as an independent prognostic biomarker predicting shorter survival. More importantly, high HOXD11 expression was positively correlated with aggressive metastatic features such as advanced pN stages, extranodal extension, pelvic lymph node and distant metastasis. Our large-scale results first supported that HOXD11 was an aggressive clinical indicator in PSCC. Subsequently, the biological functions of HOXD11 were explored in our newly established PSCC cell lines. Similar to previous findings, HOXD11 knockdown or overexpression inhibited or promoted colony formation, cell proliferation, migration and invasion *in vitro* and subcutaneous tumor growth *in vivo*. Uniquely, we employed the footpad xenograft model to simulate the metastatic pattern of PSCC for the first time. The observations further demonstrated that HOXD11 not only inhibited tumorigenicity but also reduced regional lymph node metastatic burden *in vivo*. Consequently, we clarified the functional role of HOXD11 in tumor progression and metastasis and explored the underlying molecular mechanisms.

To understand the downstream mechanisms of HOXD11, we first analyzed the differentially expressed mRNA-seq between HOXD11-silenced Pen12 and negative control cells by functional enrichment analysis and found that EMT was involved in the tumor progression of PSCC. EMT is an evolutionarily conserved process in tumor metastasis that enhances mobility, invasion, and resistance to apoptotic stimuli[41]. EMT-derived tumor cells acquire stem cell properties by reducing the polarity of epithelial cells and inducing mesenchymal, fibroblast-like properties[42]. One of the hallmark features of EMT is the degradation of ECM to decrease adherent junctions losing epithelial integrity, which was reminded by the following GSEA (Fig. 5C).

Subsequently, we explored the specific downstream targets by which the transcription factor HOXD11 mediated ECM degradation by qPCR, dual luciferase and ChIP-qPCR assays. Previous studies have indicated that several cell adhesion molecules and ECM components, including collagen 1 and 3 (encoded by COL1A1 and COL3A1), fibronectin (encoded by FN1), periostin (encoded by POSTN) and ECM-associated regulatory proteins (SPARC, THBS1 and CD44), modulate EMT-like transformation and can be regulated by transcription factors such as Twist, Slug and Snail[43, 44]. Our results demonstrated that HOXD11 directly bound to FN1 promoter regions and promoted the expression of FN1, which is a vital component of ECM in shaping the tumor microenvironment to promote metastasis.

FN1 is an ECM glycoprotein participating in cell proliferation, oncogenic transformation and EMT[45]. FN1 is overexpressed in multiple cancer types and is associated with tumor metastasis[28–31, 45–48].

For instance, FN1 increased the expression of VEGF to promote EMT and lymph node metastasis through FAK activation in oral squamous cell carcinoma[28, 48]. In addition, FN1 is involved in the maintenance of the FN1 receptor integrin  $\beta$ 1, inducing immunosuppression and promoting progression in glioma[49]. In this study, we first demonstrated that silencing FN1 inhibited the capability of cell invasion in PSCC by Transwell assays. More importantly, knockdown of FN1 also relieved the aggressiveness in HOXD11-overexpressing cells, indicating that FN1 was an essential and indispensable mediator in HOXD11-mediated PSCC tumor progression.

Next, we investigated the detailed mechanisms of HOXD11/FN1-induced ECM degradation in PSCC. Numerous studies have clarified that one of the drivers of EMT-associated ECM degradation is proteolytic digestion by matrix metalloproteinases (MMPs)[30, 45]. FN1 upregulation has been reported to activate MMP2 and MMP9 via the FAK and PI3K/Akt pathways, promoting tumor metastasis in lung, gastric, breast, ovarian and cervical cancer[28, 50–52]. In addition, fibronectin proteins, similar to extracellular glues, can specifically bind with a large number of molecules, such as other components of the extracellular matrix, cell adhesion molecules and MMPs, to modulate the progressive tumor microenvironment[45]. Therefore, we detected the expression levels of HOXD11, FN1, MMP2 and MMP9 in PSCC patients and verified that overexpression of FN1 was positively correlated with MMP2 and MMP9. WB and IF assays indicated that HOXD11 promoted FN1 transcription and induced the expression of MMP2 and MMP9 to degrade ECM and improve metastasis via an EMT-like phenotype in PSCC.

Finally, we also searched for the potential upstream regulator targeting to HOXD11. MiRNAs are dominant small noncoding RNAs that regulate epigenetic processes via interference of transcription and translation to silence gene expression[32]. However, miRNA-mediated regulation of HOXD11 has not been reported yet. In this study, the analysis of the HOXD11 3'UTR revealed the presence of binding sites with miR-138-5p that suggested the post transcriptional control exerted on HOXD11. Besides, miR-138-5p serves as a tumor suppressor via targeting and repressing the expression of HOXD11, contributes to PSCC carcinogenesis through inhibited tumor cell invasion.

In summary, we explored the available oncogene HOXD11, which is overexpressed in PSCC and is associated with lymph node metastasis and poor patient prognoses. Low expression of miR-138-5p in tumors leads to overexpression of HOXD11, which induced FN1 transcription and increased MMP2 and MMP9 expression to degrade ECM and promoted tumor metastasis *in vivo* and *in vitro*. We demonstrated that HOXD11 is a novel therapeutic target mediated by miR-138-5p promoting tumor metastasis of PSCC via the FN1/MMP2/MMP9 molecular pathway.

## Conclusions

In this study, we explored the available oncogene HOXD11, which is overexpressed in PSCC and is associated with lymph node metastasis and poor patient prognoses. HOXD11 was mediated by miR-138-5p and induced FN1 transcription and increased MMP2 and MMP9 expression to degrade ECM and

promoted tumor metastasis *in vivo* and *in vitro*. Our studies provide valuable insights into the molecular mechanism of tumor metastasis and suggest a therapeutic target in PSCC.

## List Of Abbreviations

CCK-8

cell counting kit-8

ChIP

chromatin immunoprecipitation

CI

confidence interval

CSS

cancer-specific survival

DMEM

Dulbecco's Modified Eagle's Medium

ECM

extracellular matrix

EMT

epithelial mesenchymal transition

ENE

extranodal extension

FN1

fibronectin 1

GO

Gene Ontology

GSEA

gene-set enrichment analysis

HaCaT

human immortalized keratinocytes

HOXD11

homeobox D11

HR

hazard ratio

ICC

immunocytochemistry

IF

immunofluorescence

IHC

immunohistochemistry

KEGG

Kyoto Encyclopedia of Genes and Genomes

LM

metastatic lymph node tissues

mRNA

messenger RNA

MMP

matrix metalloproteinase

MicroRNAs

miRNAs

N

normal squamous epithelium

NC

negative control

PCA

primary penile carcinoma

PSCC

penile squamous cell carcinoma

qPCR

quantitative polymerase chain reaction

shRNA

short hairpin RNA

siRNA

small interfering RNA

UTR

untranslated region

WB

Western blot

## Declarations

### Ethics approval and consent to participate

This study was approved by the Ethics Committee of SYSUCC (GZR2019-167). The animal experiments were approved by the Experimental Animal Ethics Committee of SYSUCC (L102012019002V).

### Consent for publication

The informed consent was obtained from all of the PSCC patients (GZR2019-167). Written informed consent for publication of their clinical details was obtained from the patients. All of the authors agreed with the content of the paper and agreed to publish.

### Availability of data and materials

The datasets supporting the conclusions of this article are available from the corresponding author on reasonable request. The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit platform ([www.researchdata.org.cn](http://www.researchdata.org.cn)).

### Competing interests

The authors declare no conflicts of interest.

### Funding

This study was supported by the Sun Yat-sen University Cancer Center Medical Scientist Training Program (No. 14zxqk08 to Kai Yao), the Natural Science Foundation of Guangdong Province (No. 2019A1515010197 and No. 2022A1515012318 to Kai Yao) and the Natural Science Foundation of Chongqing (No. cstc2019jcyj-msxmX0420 to Gangjun Yuan).

### Authors' contributions

TXL, WYJ and YK were the contributor in writing the manuscript. WZM and ZYT were responsible for the sample collection. TXL, LSH and TY performed the experiments *in vitro*. CD and YGJ conducted the statistical analysis. WYJ was responsible for the animal experiments. CD, YGJ and YK reviewed the article data. YGJ and YK designed the supported the study. All authors read and approved the final manuscript.

### Acknowledgements

We appreciate Lilin Liu and Keming Chen for providing pathological assistance.

### Author details

<sup>1</sup>Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China

<sup>2</sup>State Key Laboratory of Oncology in Southern China, Guangzhou 510060, China

<sup>3</sup>Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China

<sup>4</sup>Department of Urology Oncological Surgery, Chongqing University Cancer Hospital, Chongqing, 400030, China

<sup>5</sup>Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing, 400030, China

## References

1. Ficarra, V., et al., *Prognostic factors in penile cancer*. *Urology*, 2010. **76**(2 Suppl 1): p. S66-73.
2. Christodoulidou, M., et al., *Epidemiology of penile cancer*. *Curr Probl Cancer*, 2015. **39**(3): p. 126–36.

3. Hakenberg, O.W., et al., *The Diagnosis and Treatment of Penile Cancer*. Dtsch Arztebl Int, 2018. **115**(39): p. 646–652.
4. Leone, A., et al., *Contemporary management of patients with penile cancer and lymph node metastasis*. Nat Rev Urol, 2017. **14**(6): p. 335–347.
5. O'Brien, J.S., et al., *Penile Cancer: Contemporary Lymph Node Management*. J Urol, 2017. **197**(6): p. 1387–1395.
6. Hu, J., et al., *Predictors of inguinal lymph node metastasis in penile cancer patients: a meta-analysis of retrospective studies*. Cancer Manag Res, 2019. **11**: p. 6425–6441.
7. Agarwal, G., P.E. Gupta S Fau - Spiess, and P.E. Spiess, Novel targeted therapies for the treatment of penile cancer. (1746-045X (Electronic)).
8. Vanthoor, J., G. Vos, and M.A.-O. Albersen, *Penile cancer: potential target for immunotherapy?* (1433–8726 (Electronic)).
9. Gupta, S. and G. Sonpavde, Emerging Systemic Therapies for the Management of Penile Cancer. (1558-318X (Electronic)).
10. Panic, A., et al., *The Biomarker Potential of Caveolin-1 in Penile Cancer*. (2234-943X (Print)).
11. Busso-Lopes, A.F., et al., *Genomic profiling of human penile carcinoma predicts worse prognosis and survival*. Cancer Prev Res (Phila), 2015. **8**(2): p. 149–56.
12. Zhou, Q.H., et al., *Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients*. Cancer Commun (Lond), 2020. **40**(1): p. 3–15.
13. Tan, X., et al., *Molecular stratification by BCL2A1 and AIM2 provides additional prognostic value in penile squamous cell carcinoma*. (1838–7640 (Electronic)).
14. Zhou, Q.H., et al., *Elevated serum LAMC2 is associated with lymph node metastasis and predicts poor prognosis in penile squamous cell carcinoma*. Cancer Manag Res, 2018. **10**: p. 2983–2995.
15. de Barros, E.L.B.R., et al., *HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma*. Tumour Biol, 2016. **37**(11): p. 15087–15096.
16. Paco, A., et al., *Roles of the HOX Proteins in Cancer Invasion and Metastasis*. Cancers (Basel), 2020. **13**(1).
17. Sharpe, D.J., et al., *POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer*. Oncotarget, 2014. **5**(18): p. 8803–8815.
18. Liu, S., et al., *HOXB7 promotes malignant progression by activating the TGFbeta signaling pathway*. Cancer Res, 2015. **75**(4): p. 709–19.
19. von Heyking, K., et al., *The posterior HOXD locus: Its contribution to phenotype and malignancy of Ewing sarcoma*. Oncotarget, 2016. **7**(27): p. 41767–41780.
20. Wang, J., et al., *Abnormal expression of HOXD11 promotes the malignant behavior of glioma cells and leads to poor prognosis of glioma patients*. PeerJ, 2021. **9**: p. e10820.

21. Tan, X.A.-O., et al., *RAB20 Promotes Proliferation via G2/M Phase through the Chk1/cdc25c/cdc2-cyclinB1 Pathway in Penile Squamous Cell Carcinoma*. *LID – 10.3390/cancers14051106 [doi] LID – 1106*. (2072–6694 (Print)).
22. Camp, R.L., D.L. Dolled-Filhart M Fau - Rimm, and D.L. Rimm, *X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization*. (1078 – 0432 (Print)).
23. McGeary, S.E., et al., *The biochemical basis of microRNA targeting efficacy*. *Science*, 2019. **366**(6472).
24. Li, J.H., et al., *starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data*. *Nucleic Acids Res*, 2014. **42**(Database issue): p. D92-7.
25. Wong, N.W., et al., *OncomiR: an online resource for exploring pan-cancer microRNA dysregulation*. *Bioinformatics*, 2018. **34**(4): p. 713–715.
26. Lanczky, A. and B. Györfy, *Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation*. *J Med Internet Res*, 2021. **23**(7): p. e27633.
27. Kimura, H., *Histone modifications for human epigenome analysis*. (1435-232X (Electronic)).
28. Meng, X.N., et al., *Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion*. *Br J Cancer*, 2009. **101**(2): p. 327–34.
29. Serres, E., et al., *Fibronectin expression in glioblastomas promotes cell cohesion, collective invasion of basement membrane in vitro and orthotopic tumor growth in mice*. *Oncogene*, 2014. **33**(26): p. 3451–62.
30. Xu, T.-P., et al., *Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression*. *Journal of Hematology & Oncology*, 2014. **7**: p. 63.
31. Du, J., et al., *The novel circular RNA circ-CAMK2A enhances lung adenocarcinoma metastasis by regulating the miR-615-5p/fibronectin 1 pathway*. *Cell Mol Biol Lett*, 2019. **24**: p. 72.
32. Lu, T.X. and M.E. Rothenberg, *MicroRNA*. *J Allergy Clin Immunol*, 2018. **141**(4): p. 1202–1207.
33. Mo, M., et al., *High serum CCL20 is associated with tumor progression in penile cancer*. *J Cancer*, 2020. **11**(23): p. 6812–6822.
34. Mo, M., et al., *Serum CXCL13 Level is Associated with Tumor Progression and Unfavorable Prognosis in Penile Cancer*. *Onco Targets Ther*, 2020. **13**: p. 8757–8769.
35. Mo, M., Y. Li, and X. Hu, *Serum CXCL5 level is associated with tumor progression in penile cancer*. *Biosci Rep*, 2021. **41**(1).
36. Harada, H., et al., *Lung cancer risk stratification using methylation profile in the oral epithelium*. *Asian Cardiovasc Thorac Ann*, 2019. **27**(2): p. 87–92.
37. Xu, W., et al., *Genome-Wide Plasma Cell-Free DNA Methylation Profiling Identifies Potential Biomarkers for Lung Cancer*. *Dis Markers*, 2019. **2019**: p. 4108474.
38. Cai, L.Y., et al., *Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers*. (0024–3205 (Print)).

39. Miyamoto, K., et al., *Identification of 20 genes aberrantly methylated in human breast cancers*. (0020-7136 (Print)).
40. Rodrigues, M., et al., *Homeobox gene amplification and methylation in oral squamous cell carcinoma*. Arch Oral Biol, 2021. **129**: p. 105195.
41. Pastushenko, I. and C. Blanpain, *EMT Transition States during Tumor Progression and Metastasis*. (1879–3088 (Electronic)).
42. Bakir, B., et al., *EMT, MET, Plasticity, and Tumor Metastasis*. (1879–3088 (Electronic)).
43. Majidpoor, J. and K.A.-O. Mortezaee, *Steps in metastasis: an updated review*. (1559-131X (Electronic)).
44. Paolillo, M. and S. Schinelli, *Extracellular Matrix Alterations in Metastatic Processes*. LID – 10.3390/ijms20194947 [doi] LID – 4947. (1422-0067 (Electronic)).
45. Efthymiou, G., et al., *Shaping Up the Tumor Microenvironment With Cellular Fibronectin*. Front Oncol, 2020. **10**: p. 641.
46. Xu, X., et al., *Characterization of genome-wide TFCP2 targets in hepatocellular carcinoma: implication of targets FN1 and TJP1 in metastasis*. J Exp Clin Cancer Res, 2015. **34**: p. 6.
47. Nam, J.M., et al., *Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin*. Cancer Res, 2010. **70**(13): p. 5238–48.
48. Morita, Y., et al., *Cellular fibronectin 1 promotes VEGF-C expression, lymphangiogenesis and lymph node metastasis associated with human oral squamous cell carcinoma*. Clin Exp Metastasis, 2015. **32**(7): p. 739–53.
49. Sengupta, S., et al., *Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model*. Neoplasia, 2010. **12**(10): p. 837–47.
50. Assidicky, R., et al., *Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer*. (1573–7217 (Electronic)).
51. Qin, Z.A.-O. and C.A.-O. Zhou, *HOXA13 promotes gastric cancer progression partially via the FN1-mediated FAK/Src axis*. (2162–3619 (Print)).
52. Yi, Y., et al., *Comprehensive gene and pathway analysis of cervical cancer progression*. (1792 – 1074 (Print)).

## Tables

**Table 1.** Clinicopathological characteristics and the association with HOXD11 expression in 267 PSCC patients.

### HOXD11 IHC staining

Variable	PSCC cohort (N=267), %	Low expression (N=182), %	High expression (N=85), %	$\chi^2$	p-value <sup>a</sup>
<b>Age</b>				0.019	0.890
<55	143 (53.6)	98 (36.7)	45 (16.9)		
≥55	124 (46.4)	84 (31.5)	40 (15.0)		
<b>pT status</b>				<b>13.720</b>	<b>0.003<sup>b</sup></b>
≤pT1 <sup>c</sup>	102 (38.2)	78 (29.2)	24 (9.0)		
pT2	49 (18.4)	30 (11.2)	19 (7.1)		
pT3	104 (39.0)	71 (26.6)	33 (12.4)		
pT4	12 (4.5)	3 (1.1)	9 (3.4)		
<b>pN status</b>				<b>38.695</b>	<b>0.000</b>
N0	141 (52.8)	118 (44.2)	23 (8.6)		
N1	32 (12.0)	21 (7.9)	11 (4.1)		
N2	30 (11.2)	16 (6.0)	14 (5.2)		
N3	64 (24.0)	27 (10.1)	37 (13.9)		
<b>Metastasis</b>				<b>18.650</b>	<b>0.000<sup>b</sup></b>
M0	248 (92.9)	178 (66.7)	70 (26.2)		
M1	19 (7.1)	4 (1.5)	15 (5.6)		
<b>Clinical stage</b>				<b>33.743</b>	<b>0.000</b>
Stage	70 (26.2)	58 (21.7)	12 (4.5)		
Stage	70 (26.2)	57 (21.3)	13 (4.9)		
Stage	55 (20.6)	36 (13.5)	19 (7.1)		
Stage	72 (27.0)	31 (11.6)	41 (15.4)		
<b>Histology</b>				<b>9.006</b>	<b>0.011</b>
G1	129 (48.3)	99 (37.1)	30 (11.2)		
G2	95 (35.6)	59 (22.1)	36 (13.5)		
G3	43 (16.1)	24 (9.0)	19 (7.1)		
<b>ENE</b>				<b>23.887</b>	<b>0.000</b>

No	218 (81.6)	163 (61.0)	55 (20.6)		
Yes	49 (18.4)	19 (7.1)	30 (11.2)		
<b>PLNM<sup>d</sup></b>				<b>4.298</b>	<b>0.038</b>
No	23 (62.2)	20 (54.1)	3 (8.1)		
Yes	14 (37.8)	7 (18.9)	7 (18.9)		

<sup>a</sup>Chi-square test; <sup>b</sup>Fisher's exact test; <sup>c</sup>Included Ta, Tis and pT1 patients; <sup>d</sup>A total of 37 PSCC patients underwent pelvic lymph node dissection. ENE, extranodal extension; PLNM, Pelvic lymph node metastasis; PSCC, penile squamous cell carcinoma.


**Table 2.** Univariate and multivariate analyses of HOXD11 expression and clinicopathological features in 267 PSCC patients.

Variable	Univariate analysis <sup>a</sup>			Multivariate analysis <sup>b</sup>		
	Total N	Events (%)	5-year CSS rate (95% CI)	p-value	Hazard ratio (95% CI)	p-value
<b>HOXD11</b>				<b>0.000</b>		<b>0.016</b>
Low expression	182	43 (23.6)	0.767 (0.698-0.836)		Reference	
High expression	85	46 (54.1)	0.390 (0.267-0.513)		1.759 (1.112-2.782)	
<b>Age</b>				<b>0.400</b>		
<55	143	47 (32.9)	0.679 (0.597-0.761)		Excluded	
≥55	124	42 (33.9)	0.612 (0.512-0.712)			
<b>pT status<sup>c</sup></b>				<b>0.000</b>		<b>0.051</b>
≤pT1	102	19 (18.6)	0.815 (0.729-0.901)	Reference	Reference	-
pT2	49	18 (36.7)	0.547 (0.384-0.710)	<b>0.002</b>	1.618 (0.814-3.217)	0.170
pT3	104	41 (39.4)	0.601 (0.497-0.705)	<b>0.000</b>	1.815 (1.031-3.197)	<b>0.039</b>
pT4	12	11 (91.7)	0.000	<b>0.000</b>	3.231 (1.355-7.705)	<b>0.008</b>
<b>Histology</b>				<b>0.000</b>		<b>0.107</b>
G1	129	27 (20.9)	0.804 (0.730-0.878)	Reference	Reference	-
G2	95	33 (34.7)	0.582 (0.460-0.704)	<b>0.002</b>	1.003 (0.577-1.745)	0.990
G3	43	29 (67.4)	0.276 (0.121-0.431)	<b>0.000</b>	1.719 (0.915-3.229)	0.092
<b>pN status<sup>d</sup></b>				<b>0.000</b>		<b>0.000</b>
N0	141	14 (9.9)	0.903 (0.844-0.962)	Reference	Reference	-
N1	32	12 (37.5)	0.613 (0.431-0.795)	<b>0.000</b>	3.728 (1.699-8.176)	<b>0.001</b>
N2	30	14	0.503 (0.295-	<b>0.000</b>	4.737 (2.133-	<b>0.000</b>

		(46.7)	0.711)		10.519)	
N3	64	49 (76.6)	0.160 (0.050- 0.270)	<b>0.000</b>	7.860 (3.073- 20.104)	<b>0.000</b>
<b>Metastasis</b>				<b>0.000</b>		<b>0.005</b>
M0	248	70 (28.2)	0.703 (0.638- 0.768)		Reference	
M1	19	19 (100)	0.161 (0.028- 0.294)		2.557 (1.337- 4.890)	
<b>Clinical stage</b>				<b>0.000</b>		
Stage	70	8 (11.4)	0.773 (0.604- 0.942)	Reference	Excluded <sup>e</sup>	
Stage	70	5 (7.1)	0.944 (0.883- 1.000)	0.453		
Stage	55	21 (38.2)	0.614 (0.471- 0.757)	<b>0.000</b>		
Stage	72	55 (76.4)	0.147 (0.045- 0.249)	<b>0.000</b>		
<b>ENE</b>				<b>0.000</b>		0.278
No	218	52 (23.9)	0.755 (0.690- 0.820)		Reference	
Yes	49	37 (75.5)	0.161 (0.028- 0.294)		1.484 (0.727- 3.029)	

<sup>a</sup>Log-rank test; <sup>b</sup>Cox regression model; <sup>c</sup>There was no significant difference between pT2 and pT3 subgroup ( $\chi^2=0.001$ ;  $p=0.979$ ); <sup>d</sup>There was no significant difference between pN1 and pN2 subgroup ( $\chi^2=0.783$ ;  $p=0.376$ ); <sup>e</sup>Clinical stage was excluded from the Cox regression model as it was represented by the TNM stage. CSS, cancer-specific survival.

## Figures




**Figure 1**

***HOX genes expression patterns and clinical significance of HOXD11 in PSCC***

Total mRNA was extracted from 12 pN+ PSCC patients with corresponding N, PCA and LM tissues. (A) The HOX genes mRNA expression profile of 12 paired tissues. (B) Among the 34 HOX genes, the mRNA expression of HOXB2, HOXD10 and HOXD11 in tumors especially in LM were striking increased. (C) For each PSCC patients, HOXD11 was overexpressed step by step in PCA and LM than normal tissues. (D) The HOXD11 proteins was increased in tumor tissues and PSCC cell lines. (E) The IHC assays indicated the expression of HOXD11 in paired tissues in a pT3N3M1 PSCC patients. (F) The mRNA levels of HOXD11 were upregulated in 93 tumor tissues compared with those in 21 normal tissues. Overexpression


of HOXD11 was associated with poor pT, pN stages and ENE. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ . NS, not significant; N, normal squamous epithelium; PCA, primary carcinoma; LM, metastatic lymph node; HaCaT, human immortalized keratinocytes; IHC, immunohistochemistry; ENE, extranodal extension; PSCC, penile squamous cell carcinoma.



**Figure 2**

*HOXD11 overexpression was associated with poor clinical features and survival in 267 PSCC patients.*

Kaplan–Meier survival analysis indicated that high HOXD11 expression was associated with lower 5-year CSS rates in the 267 PSCC cohort, (B) pT2–pT4 subgroup, (C) pathological grade subgroup, (D) pN+ subgroup, (E) metastasis subgroup and (F) extranodal extension subgroup of PSCC patients. CSS, cancer-specific survival; PSCC, penile squamous cell carcinoma.




**Figure 3**

***HOXD11 promote cell proliferation and invasion in PSCC in vitro.***

After overexpressing or silencing HOXD11, PSCC cells were assessed for cell proliferation, clone formation, cell migration and invasion. Besides, rescue experiments were performed to determine to the oncogenic phenotype. (A) WB analysis for HOXD11 expression. (B) CCK-8 assays to determine the proliferative potential of HOXD11. (C) WB was performed to detect the rescue efficacy when HOXD11 was


overexpressed in shHOXD11 cells. (D) Colony formation assay, (E) transwell invasion assays (E) and wound healing assays showed that the dysregulation of HOXD11 was involved in tumorigenesis *in vitro*. (G and H) Overexpression of HOXD11 restored the inhibition of cell migration and invasion in shHOXD11 cells. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ . Statistics are presented as the means  $\pm$  SDs of three independent experiments. NS, not significant; NC, negative control; PSCC, penile squamous cell carcinoma.



**Figure 4**

***Knockdown of HOXD11 inhibited tumor growth and popliteal lymph node metastasis in vivo.***

Pen12 HOXD11-sh1 cells were injected subcutaneously to establish xenograft tumor model in BALB/c nude mice (n=6) for three weeks. (A) Knockdown of HOXD11 inhibited tumor growth *in vivo*. IHC was performed to detect the expression of HOXD11 in two groups. (B) The effect of HOXD11 on lymph nodes metastasis was explored by an inguinal and popliteal lymph node metastasis model (n=6). Knockdown of HOXD11 inhibited the volume of popliteal lymph node, and HE staining demonstrated the reduction of lymph node metastasis. \* $p < 0.05$ . NC, negative control; HE, hematoxylin-eosin.




**Figure 5**

*HOXD11 directly bounded with the promoter of FN1 in PSCC.*

(A) GO enrichment analyses between Pen12 HOXD11-shNC and HOXD11-sh1 cells indicated the significant genes enrichment involving in tumor progression. (B) The differential genes involving in EMT and cell adhesion are shown by heatmap. (C) GSEA analysis showed that knockdown of HOXD11 might

promote EMT and tumor metastasis through the degradation of ECM. (D) qPCR analysis of ECM-related markers in the indicated cells. (E) Luciferase reporter assay of FN1 and THBS1 transcriptional activity. (F) Six potential FN1 promoter binding regions with HOXD11 were predicted by JASPAR database. The chromatin stabilization of corresponding regions were detected by H3K27Ac, H3K4Me1 and H3K4Me3 by UCSC Genome Browser. (G) Detail nucleotide binding sequences of FN1 promoter and the CHIP-seq results. (H, I) Luciferase reporter and CHIP-seq assays indicated that FN1 transcriptional activity was eliminated when transfection with FN1 promoter with mutant nucleotide binding sequences of P2 sites. \*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001. KEGG, Kyoto Encyclopedia of Genes and Genomes; GO, Gene Ontology; GSEA, gene set enrichment analysis; EMT, epithelial-mesenchymal transition; ECM, extracellular matrix; CHIP, chromatin immunoprecipitation.




**Figure 6**

*HOXD11 induced the degradation of extracellular matrix via the FN1/MMP2/MMP9 pathways.*

The mRNA expression of FN1 in 24 PSCC tumors and 8 normal tissues. (B) The expression relationship of target genes in 24 PSCC patients by Pearson correlation analysis. (C, D) Western bolt and immunocytochemistry showed the decreased protein expression of FN1, MMP2 and MMP9 when

knockdown of HOXD11 in PSCC cells. (E) Immunofluorescence indicated that overexpression of HOXD11 in 149rca cells increased the expression of FN1, MMP2 and MMP9. While the expression of MMP2 and MMP9 were inhibited by siRNA-FN1transfection. (F, G) Knockdown of FN1 inhibited cell invasion in PSCC, and undermined the progressive potential of cell invasion in HOXD11 overexpression cells. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ . Statistics are presented as the means  $\pm$  SDs of three independent experiments.



**Figure 7**

***miR-138-5p repressed HOXD11 expression and inhibited cell invasion in PSCC.***

The expression relationship between miR-138-5p and HOXD11 in 24 PSCC patients. (B) The expression of miR-138-5p was down-regulated in PSCC tumors. (C) TargetScan predicted the bounding sites between miR-138-5p and HOXD11 3'UTR. (D) Luciferase reporter assays indicated that miR-138-5p directly bound

with the region of HOXD11 3'UTR. (E, F) Cell invasion activity was significantly inhibited in miR-138-5p mimics transfectants, and promoted in miR-138-5p inhibitors transfectants comparing with miR-control transfectant cells. (G, H) The invasive cells were reversed when transfecting with miR-138-5p mimics in HOXD11 overexpression 149rca cells.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryMaterials20220608finalversion.docx](#)